Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 20/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | TTR | P02766 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10511892 | 0.86 | TBK1 (0.76) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19182246 | 0.85 | TBK1 (0.74) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19197557 | 0.83 | KDM4E (0.77) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19197558 | 0.83 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL9796379 | 0.83 | TBK1 (0.76) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL10510862 | 0.81 | TBK1 (0.85) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19180575 | 0.81 | TBK1 (1.00) | TBK1IKBKE | |
| SCHEMBL19196793 | 0.80 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| Amlexanox SCHEMBL29642 | 0.80 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 | |
| SCHEMBL19199632 | 0.80 | TBK1 (1.00) | TBK1IKBKEKDM4ENPC1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217980-A1 | AMLEXANOX ANALOGS | GPR119, GLP1R, IRS1 | TBK1 494/4885IKBKE 189/4885KDM4E 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.